National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee

Michael R. Bishop, Edwin P. Alyea, Mitchell S. Cairo, J. H.Frederik Falkenburg, Carl H. June, Nicolaus Kröger, Richard F. Little, Jeffrey S. Miller, Steven Z. Pavletic, David L. Porter, Stanley R. Riddell, Koen van Besien, Alan S. Wayne, Daniel J. Weisdorf, Roy S. Wu, Sergio Giralt

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations

Abstract

The National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop's 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee's recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT.

Original languageEnglish (US)
Pages (from-to)443-454
Number of pages12
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number4
DOIs
StatePublished - Apr 2011

Bibliographical note

Funding Information:
Financial disclosure: This work was supported by the Center for Cancer Research, National Cancer Institute, Intramural Research Program .

Keywords

  • Donor lymphocyte infusion
  • Graft-versus-tumor
  • Minimal residual disease

Fingerprint

Dive into the research topics of 'National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee'. Together they form a unique fingerprint.

Cite this